<p>Eton Pharmaceuticals, Inc.（納斯達克代碼：ETON - 獲取免費報告）在週六的午盤交易中創下了新的 52 周高點。該股最高交易價格為 29.80 美元，最後交易價格為 28.90 美元，成交量為 966326 股。該股此前收盤價為 24.12 美元。</p>
<p>獲取 <strong>Eton Pharmaceuticals</strong> 的提醒：</p>
<h2>分析師評級變動</h2>
<p>幾位股票分析師對該股發佈了報告。HC Wainwright 將 Eton Pharmaceuticals 的目標股價從 37.00 美元上調至 52.00 美元，並在 3 月 20 日的研究報告中給予該公司 “買入” 評級。Weiss Ratings 在 4 月 21 日的研究報告中重申了對 Eton Pharmaceuticals 的 “賣出（d-）” 評級。Zacks Research 在 4 月 17 日的研究報告中將 Eton Pharmaceuticals 的評級從 “強力買入” 下調至 “持有”。B. Riley Financial 在 3 月 20 日的研究報告中將 Eton Pharmaceuticals 的目標價從 26.00 美元上調至 31.00 美元，並給予該股 “買入” 評級。最後，華爾街 Zen 在 3 月 21 日的研究報告中將 Eton Pharmaceuticals 的評級從 “持有” 上調至 “買入”。三位股票研究分析師給予該股 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，Eton Pharmaceuticals 的共識評級為 “持有”，共識目標價為 39.33 美元。</p>
<p><strong>查看我們對 ETON 的最新分析</strong></p>
<h2>Eton Pharmaceuticals 股票表現</h2>
<p>該公司的債務與股本比率為 0.83，流動比率為 1.57，速動比率為 1.17。該公司的 50 日移動平均價格為 21.94 美元，200 日移動平均價格為 18.48 美元。該公司的市值為 7.907 億美金，市盈率為-160.55，貝塔值為 0.82。</p>
<p>Eton Pharmaceuticals（納斯達克代碼：ETON - 獲取免費報告）在 3 月 19 日星期四發佈了季度財報。該公司報告每股收益為 0.05 美元，低於共識預期的 0.12 美元（差額為 0.07 美元）。Eton Pharmaceuticals 的股本回報率為-2.60%，淨利潤率為-5.75%。該公司季度收入為 2128 萬美元，而分析師預期為 2058 萬美元。平均而言，股票研究分析師預計 Eton Pharmaceuticals, Inc.在當前財年將發佈 0.82 美元的每股收益。</p>
<h2>機構投資者對 Eton Pharmaceuticals 的看法</h2>
<p>大型投資者最近買入和賣出了該股的股份。阿拉斯加州財政部在第三季度新購入 Eton Pharmaceuticals 的股份，價值 30,000 美元。Quarry LP 在第三季度新購入 Eton Pharmaceuticals 的股份，價值 37,000 美元。凱通國際資產管理有限公司在第四季度新購入 Eton Pharmaceuticals 的股份，價值 44,000 美元。Legal &amp; General Group Plc 在第二季度新購入 Eton Pharmaceuticals 的股份，價值 41,000 美元。最後，中國泛海資產管理有限公司在第四季度新購入 Eton Pharmaceuticals 的股份，價值 74,000 美元。目前 27.86% 的股份由機構投資者和對沖基金持有。</p>
<h2>關於 Eton Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Eton Pharmaceuticals, Inc.是一家專注於開發、生產和商業化針對罕見和被忽視疾病的仿製藥和專有藥品的專業製藥公司。公司總部位於佛羅里達州西棕櫚灘，利用其在激素療法和複雜分子方面的專業知識，解決患者需求高而競爭有限的治療領域。自 2016 年成立以來，Eton 一直致力於建立一個多元化的產品組合，將成熟的仿製藥與針對性的品牌產品相結合。</p>
<p>該公司的產品線包括甲狀腺激素替代品，如干燥甲狀腺和利奧甲狀腺素，以及用於弓形蟲病的吡美莫司片。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票超過 Eton Pharmaceuticals</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Eton Pharmaceuticals 嗎？</h2>
<p>在你考慮 Eton Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Eton Pharmaceuticals 並不在名單上。</p>
<p>雖然 Eton Pharmaceuticals 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ETON

紐交所高增長板生物技術指數 ETF - First Trust

動態生物技術與基因組 ETF - Invesco

<p>Eton Pharmaceuticals（納斯達克代碼：ETON）達到了新的 12 個月高點 29.80 美元，收盤價為 28.90 美元，交易量顯著。分析師的評級各不相同：HC Wainwright 將其目標價上調至 52 美元（買入），而 Weiss Ratings 維持賣出評級。該公司報告的收入為 2128 萬美元，但未能達到每股收益預期。機構投資者持有 27.86% 的股份。Eton 專注於開發針對罕見疾病的藥品，市值為 7.907 億美金</p>

<p>Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) hit a new 52-week high during mid-day trading on Saturday . The stock traded as high as $29.80 and last traded at $28.90, with a volume of 966326 shares trading hands. The stock had previously closed at $24.12.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals, Inc.（納斯達克代碼：ETON - 獲取免費報告）在週六的午盤交易中創下了新的 52 周高點。該股最高交易價格為 29.80 美元，最後交易價格為 28.90 美元，成交量為 966326 股。該股此前收盤價為 24.12 美元。</p>
</div><p>Get <strong>Eton Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Eton Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Several equities analysts have issued reports on the stock. HC Wainwright upped their price target on shares of Eton Pharmaceuticals from $37.00 to $52.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, March 20th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Eton Pharmaceuticals in a research report on Tuesday, April 21st. Zacks Research cut shares of Eton Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Friday, April 17th. B. Riley Financial increased their price objective on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, March 20th. Finally, Wall Street Zen upgraded shares of Eton Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, March 21st. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Eton Pharmaceuticals has a consensus rating of &#34;Hold&#34; and a consensus target price of $39.33.</p>
<div class="lb-trans"><p>幾位股票分析師對該股發佈了報告。HC Wainwright 將 Eton Pharmaceuticals 的目標股價從 37.00 美元上調至 52.00 美元，並在 3 月 20 日的研究報告中給予該公司 “買入” 評級。Weiss Ratings 在 4 月 21 日的研究報告中重申了對 Eton Pharmaceuticals 的 “賣出（d-）” 評級。Zacks Research 在 4 月 17 日的研究報告中將 Eton Pharmaceuticals 的評級從 “強力買入” 下調至 “持有”。B. Riley Financial 在 3 月 20 日的研究報告中將 Eton Pharmaceuticals 的目標價從 26.00 美元上調至 31.00 美元，並給予該股 “買入” 評級。最後，華爾街 Zen 在 3 月 21 日的研究報告中將 Eton Pharmaceuticals 的評級從 “持有” 上調至 “買入”。三位股票研究分析師給予該股 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，Eton Pharmaceuticals 的共識評級為 “持有”，共識目標價為 39.33 美元。</p>
</div><p><strong>View Our Latest Analysis on ETON</strong></p>
<div class="lb-trans"><p><strong>查看我們對 ETON 的最新分析</strong></p>
</div><h2>Eton Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Eton Pharmaceuticals 股票表現</h2>
</div><p>The company has a debt-to-equity ratio of 0.83, a current ratio of 1.57 and a quick ratio of 1.17. The company's 50-day moving average price is $21.94 and its two-hundred day moving average price is $18.48. The company has a market capitalization of $790.70 million, a price-to-earnings ratio of -160.55 and a beta of 0.82.</p>
<div class="lb-trans"><p>該公司的債務與股本比率為 0.83，流動比率為 1.57，速動比率為 1.17。該公司的 50 日移動平均價格為 21.94 美元，200 日移動平均價格為 18.48 美元。該公司的市值為 7.907 億美金，市盈率為-160.55，貝塔值為 0.82。</p>
</div><p>Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings data on Thursday, March 19th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.07). Eton Pharmaceuticals had a negative return on equity of 2.60% and a negative net margin of 5.75%.The firm had revenue of $21.28 million for the quarter, compared to analyst estimates of $20.58 million. On average, equities research analysts anticipate that Eton Pharmaceuticals, Inc. will post 0.82 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals（納斯達克代碼：ETON - 獲取免費報告）在 3 月 19 日星期四發佈了季度財報。該公司報告每股收益為 0.05 美元，低於共識預期的 0.12 美元（差額為 0.07 美元）。Eton Pharmaceuticals 的股本回報率為-2.60%，淨利潤率為-5.75%。該公司季度收入為 2128 萬美元，而分析師預期為 2058 萬美元。平均而言，股票研究分析師預計 Eton Pharmaceuticals, Inc.在當前財年將發佈 0.82 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On Eton Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Eton Pharmaceuticals 的看法</h2>
</div><p>Large investors have recently bought and sold shares of the stock. State of Alaska Department of Revenue acquired a new stake in Eton Pharmaceuticals in the third quarter worth $30,000. Quarry LP acquired a new stake in Eton Pharmaceuticals in the third quarter worth $37,000. Caitong International Asset Management Co. Ltd acquired a new stake in Eton Pharmaceuticals in the fourth quarter worth $44,000. Legal &amp; General Group Plc acquired a new stake in Eton Pharmaceuticals in the second quarter worth $41,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Eton Pharmaceuticals in the fourth quarter worth $74,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>大型投資者最近買入和賣出了該股的股份。阿拉斯加州財政部在第三季度新購入 Eton Pharmaceuticals 的股份，價值 30,000 美元。Quarry LP 在第三季度新購入 Eton Pharmaceuticals 的股份，價值 37,000 美元。凱通國際資產管理有限公司在第四季度新購入 Eton Pharmaceuticals 的股份，價值 44,000 美元。Legal &amp; General Group Plc 在第二季度新購入 Eton Pharmaceuticals 的股份，價值 41,000 美元。最後，中國泛海資產管理有限公司在第四季度新購入 Eton Pharmaceuticals 的股份，價值 74,000 美元。目前 27.86% 的股份由機構投資者和對沖基金持有。</p>
</div><h2>About Eton Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Eton Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals, Inc.是一家專注於開發、生產和商業化針對罕見和被忽視疾病的仿製藥和專有藥品的專業製藥公司。公司總部位於佛羅里達州西棕櫚灘，利用其在激素療法和複雜分子方面的專業知識，解決患者需求高而競爭有限的治療領域。自 2016 年成立以來，Eton 一直致力於建立一個多元化的產品組合，將成熟的仿製藥與針對性的品牌產品相結合。</p>
</div><p>The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.</p>
<div class="lb-trans"><p>該公司的產品線包括甲狀腺激素替代品，如干燥甲狀腺和利奧甲狀腺素，以及用於弓形蟲病的吡美莫司片。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Eton Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Eton Pharmaceuticals</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eton Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Eton Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Eton Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Eton Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Eton Pharmaceuticals 並不在名單上。</p>
</div><p>While Eton Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Eton Pharmaceuticals 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Eton Pharmaceuticals (NASDAQ:ETON) Reaches New 12-Month High  - Time to Buy?

Market Beat

Eton Pharmaceuticals

Invesco Nasdaq Biotechnology ETF

醫藥突破 ETF - ALPS

標普生物技術 ETF - SPDR

美國制藥 ETF - iShares

醫療業 ETF - Vanguard

生物科技 ETF - VanEck Vectors

2 倍做多納斯達克生物技術 ETF - ProShares

納斯達克生物科技指數 ETF - iShares Nasdaq

醫療業 ETF - SPDR

基因改革 ETF - ARK

標普生物技術 3 倍做多 - Direxion

Legal & General Group Plc

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B. Riley Financial-存託優先股A

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

Eton Pharmaceuticals（NASDAQ:ETON）創下新的 12 個月高點 - 現在是買入的好時機嗎？